Bausch + Lomb licenses surgical tech; CrossBay picks up regulatory nods for biopsy device;

@FierceMedDev: Ariosa faces new patent pushback from rival Illumina. Story | Follow @FierceMedDev

@VarunSaxena2: RT from FierceMedicalDevices: Covidien quarterly sales up 3% to $2.6 billion. News | Follow @VarunSaxena2

@EmilyWFierce: New device from scientists @MESImedical could speed up the diagnosis for peripheral artery disease. More | Follow @EmilyWFierce

@MichaelGFierce: Imaging technique maps transdermal drug migration. Item | Follow @MichaelGFierce

> Bausch + Lomb has signed a deal with Cirle to use the company's surgical navigation system for eye procedures. News

> CrossBay Medical picked up FDA, Health Canada and CE mark clearances for its SonoSure device, used for imaging and biopsy collection. More

> Private equity outfits GTCR and Golden Gate Capital are the two remaining bidders for Phillips-Medisize, a contract device manufacturer, according to The Wall Street Journal. Item

Biotech News

@FierceBiotech: Forest lands Furiex and expands GI business in $1.5B buyout deal. Story | Follow @FierceBiotech

@JohnCFierce: Pfizer and AstraZeneca spent a combined $11.5B on R&D last year, with mixed results. You can imagine how much of that would be cut after a merger. | Follow @JohnCFierce

@DamianFierce: Biotech is finally invited to the deal parade: Forest buying Furiex for $1.1B plus an eluxadoline-tied CVR. Release | Follow @DamianFierce

@EmilyMFierce: "We're at a very unique point in biology," says Johns Hopkins Medicine's Aravinda Chakrararti. Biology is complicated but not random. | Follow @EmilyMFierce

> Ignoring harsh lessons, Pfizer pursues $100B deal to buy struggling AstraZeneca. More

> OncoGenex, Teva flag a failed PhIII for prostate cancer drug. Article

Pharma News

@FiercePharma: Why pay $100B for AstraZeneca? Let Pfizer's CEO count the reasons. Story | Follow @FiercePharma

@TracyStaton: Which Big Pharmas aren't making deal headlines (at least not yet)? Roche. Sanofi. J&J. Bristol-Myers. They're definitely outnumbered. | Follow @TracyStaton

@EricPFierce: Analyst says Bayer may sale plastics biz for $10B, use that to help fund deal for Merck OTC biz, or Zoetis. More | Follow @EricPFierce

@CarlyHFierce: ICYMI Friday... Experts: MERS vaccine is possible--but is it worth it? Article | Follow @CarlyHFierce

> Experts foresee premium pricing for overdose-fighting injector Evzio. Item

> Irreconcilable differences? Allergan investors wary of suitor Valeant's cost-slashing style. More

> Merck could snag $14B from consumer biz as Bayer, Reckitt race to the wire. News

CRO News

> Biogen and Quintiles ink a deep-seated deal to boost R&D efficiency. More

> Medidata's sales leap on spike in eClinical demand. Story

> Harlan picks a partner and expands in Southeast Asia. Article

> Catalent ticks up revenue as IPO pends. Report

> Big Pharma megadeals could spell trouble for CROs. News

> Bristol-Myers deepens CMO deal with Samsung. Item

Biotech IT News

> NIH lays out plan to work exome data into clinical research. More

> Wellcome Trust order helps Illumina blast past HiSeq X Ten sale forecasts. Story

> Y Combinator seeking software-enabled biotechs after raising funding limit. Article

> Feds fret over threat of healthcare data theft. News

> U.K. seeks help prioritizing $3.4B of Big Data projects. Report

> Google patents show plans for smart contact lenses. Item

Suggested Articles

LabCorp, Philips and Mount Sinai are coming together to develop an AI-driven pathology center of excellence, aimed initially at cancer diagnosis.

The FDA followed through with plans to end its Alternative Summary Reporting program, making 20 years’ worth of device safety data publicly available.

Janssen tapped Resolution Bioscience to develop a companion diagnostic for Zejula in patients with metastatic castration-resistant prostate cancer.